Mutated Ptpn11 alters leukemic stem cell frequency and reduces the sensitivity of acute myeloid leukemia cells to Mcl1 inhibition

L. Chen, W. Chen, M. Mysliwski, J. Serio, J. Ropa, F. A. Abulwerdi, Rebecca Chan, J. P. Patel, M. S. Tallman, E. Paietta, A. Melnick, R. L. Levine, O. Abdel-Wahab, Z. Nikolovska-Coleska, A. G. Muntean

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

PTPN11 encodes the Shp2 non-receptor protein-tyrosine phosphatase implicated in several signaling pathways. Activating mutations in Shp2 are commonly associated with juvenile myelomonocytic leukemia but are not as well defined in other neoplasms. Here we report that Shp2 mutations occur in human acute myeloid leukemia (AML) at a rate of 6.6% (6/91) in the ECOG E1900 data set. We examined the role of mutated Shp2 in leukemias harboring MLL translocations, which co-occur in human AML. The hyperactive Shp2E76K mutant, commonly observed in leukemia patients, significantly accelerated MLL-AF9-mediated leukemogenesis in vivo. Shp2E76K increased leukemic stem cell frequency and affords MLL-AF9 leukemic cells IL3 cytokine hypersensitivity. As Shp2 is reported to regulate anti-apoptotic genes, we investigated Bcl2, Bcl-xL and Mcl1 expression in MLL-AF9 leukemic cells with and without Shp2E76K. Although the Bcl2 family of genes was upregulated in Shp2E76K cells, Mcl1 showed the highest upregulation in MLL-AF9 cells in response to Shp2E76K. Indeed, expression of Mcl1 in MLL-AF9 cells phenocopies expression of Shp2E76K, suggesting Shp2 mutations cooperate through activation of anti-apoptotic genes. Finally, we show Shp2E76K mutations reduce sensitivity of AML cells to small-molecule-mediated Mcl1 inhibition, suggesting reduced efficacy of drugs targeting MCL1 in patients with hyperactive Shp2.

Original languageEnglish
Pages (from-to)1290-1300
Number of pages11
JournalLeukemia
Volume29
Issue number6
DOIs
StatePublished - Jun 9 2015

Fingerprint

Myeloid Cells
Acute Myeloid Leukemia
Stem Cells
Mutation
Non-Receptor Protein Tyrosine Phosphatases
Leukemia
Juvenile Myelomonocytic Leukemia
Genes
Drug Delivery Systems
Hypersensitivity
Up-Regulation
Cytokines
Neoplasms

ASJC Scopus subject areas

  • Hematology
  • Cancer Research
  • Anesthesiology and Pain Medicine

Cite this

Chen, L., Chen, W., Mysliwski, M., Serio, J., Ropa, J., Abulwerdi, F. A., ... Muntean, A. G. (2015). Mutated Ptpn11 alters leukemic stem cell frequency and reduces the sensitivity of acute myeloid leukemia cells to Mcl1 inhibition. Leukemia, 29(6), 1290-1300. https://doi.org/10.1038/leu.2015.18

Mutated Ptpn11 alters leukemic stem cell frequency and reduces the sensitivity of acute myeloid leukemia cells to Mcl1 inhibition. / Chen, L.; Chen, W.; Mysliwski, M.; Serio, J.; Ropa, J.; Abulwerdi, F. A.; Chan, Rebecca; Patel, J. P.; Tallman, M. S.; Paietta, E.; Melnick, A.; Levine, R. L.; Abdel-Wahab, O.; Nikolovska-Coleska, Z.; Muntean, A. G.

In: Leukemia, Vol. 29, No. 6, 09.06.2015, p. 1290-1300.

Research output: Contribution to journalArticle

Chen, L, Chen, W, Mysliwski, M, Serio, J, Ropa, J, Abulwerdi, FA, Chan, R, Patel, JP, Tallman, MS, Paietta, E, Melnick, A, Levine, RL, Abdel-Wahab, O, Nikolovska-Coleska, Z & Muntean, AG 2015, 'Mutated Ptpn11 alters leukemic stem cell frequency and reduces the sensitivity of acute myeloid leukemia cells to Mcl1 inhibition', Leukemia, vol. 29, no. 6, pp. 1290-1300. https://doi.org/10.1038/leu.2015.18
Chen, L. ; Chen, W. ; Mysliwski, M. ; Serio, J. ; Ropa, J. ; Abulwerdi, F. A. ; Chan, Rebecca ; Patel, J. P. ; Tallman, M. S. ; Paietta, E. ; Melnick, A. ; Levine, R. L. ; Abdel-Wahab, O. ; Nikolovska-Coleska, Z. ; Muntean, A. G. / Mutated Ptpn11 alters leukemic stem cell frequency and reduces the sensitivity of acute myeloid leukemia cells to Mcl1 inhibition. In: Leukemia. 2015 ; Vol. 29, No. 6. pp. 1290-1300.
@article{9c169246b4304c8baea902c4973b421a,
title = "Mutated Ptpn11 alters leukemic stem cell frequency and reduces the sensitivity of acute myeloid leukemia cells to Mcl1 inhibition",
abstract = "PTPN11 encodes the Shp2 non-receptor protein-tyrosine phosphatase implicated in several signaling pathways. Activating mutations in Shp2 are commonly associated with juvenile myelomonocytic leukemia but are not as well defined in other neoplasms. Here we report that Shp2 mutations occur in human acute myeloid leukemia (AML) at a rate of 6.6{\%} (6/91) in the ECOG E1900 data set. We examined the role of mutated Shp2 in leukemias harboring MLL translocations, which co-occur in human AML. The hyperactive Shp2E76K mutant, commonly observed in leukemia patients, significantly accelerated MLL-AF9-mediated leukemogenesis in vivo. Shp2E76K increased leukemic stem cell frequency and affords MLL-AF9 leukemic cells IL3 cytokine hypersensitivity. As Shp2 is reported to regulate anti-apoptotic genes, we investigated Bcl2, Bcl-xL and Mcl1 expression in MLL-AF9 leukemic cells with and without Shp2E76K. Although the Bcl2 family of genes was upregulated in Shp2E76K cells, Mcl1 showed the highest upregulation in MLL-AF9 cells in response to Shp2E76K. Indeed, expression of Mcl1 in MLL-AF9 cells phenocopies expression of Shp2E76K, suggesting Shp2 mutations cooperate through activation of anti-apoptotic genes. Finally, we show Shp2E76K mutations reduce sensitivity of AML cells to small-molecule-mediated Mcl1 inhibition, suggesting reduced efficacy of drugs targeting MCL1 in patients with hyperactive Shp2.",
author = "L. Chen and W. Chen and M. Mysliwski and J. Serio and J. Ropa and Abulwerdi, {F. A.} and Rebecca Chan and Patel, {J. P.} and Tallman, {M. S.} and E. Paietta and A. Melnick and Levine, {R. L.} and O. Abdel-Wahab and Z. Nikolovska-Coleska and Muntean, {A. G.}",
year = "2015",
month = "6",
day = "9",
doi = "10.1038/leu.2015.18",
language = "English",
volume = "29",
pages = "1290--1300",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Mutated Ptpn11 alters leukemic stem cell frequency and reduces the sensitivity of acute myeloid leukemia cells to Mcl1 inhibition

AU - Chen, L.

AU - Chen, W.

AU - Mysliwski, M.

AU - Serio, J.

AU - Ropa, J.

AU - Abulwerdi, F. A.

AU - Chan, Rebecca

AU - Patel, J. P.

AU - Tallman, M. S.

AU - Paietta, E.

AU - Melnick, A.

AU - Levine, R. L.

AU - Abdel-Wahab, O.

AU - Nikolovska-Coleska, Z.

AU - Muntean, A. G.

PY - 2015/6/9

Y1 - 2015/6/9

N2 - PTPN11 encodes the Shp2 non-receptor protein-tyrosine phosphatase implicated in several signaling pathways. Activating mutations in Shp2 are commonly associated with juvenile myelomonocytic leukemia but are not as well defined in other neoplasms. Here we report that Shp2 mutations occur in human acute myeloid leukemia (AML) at a rate of 6.6% (6/91) in the ECOG E1900 data set. We examined the role of mutated Shp2 in leukemias harboring MLL translocations, which co-occur in human AML. The hyperactive Shp2E76K mutant, commonly observed in leukemia patients, significantly accelerated MLL-AF9-mediated leukemogenesis in vivo. Shp2E76K increased leukemic stem cell frequency and affords MLL-AF9 leukemic cells IL3 cytokine hypersensitivity. As Shp2 is reported to regulate anti-apoptotic genes, we investigated Bcl2, Bcl-xL and Mcl1 expression in MLL-AF9 leukemic cells with and without Shp2E76K. Although the Bcl2 family of genes was upregulated in Shp2E76K cells, Mcl1 showed the highest upregulation in MLL-AF9 cells in response to Shp2E76K. Indeed, expression of Mcl1 in MLL-AF9 cells phenocopies expression of Shp2E76K, suggesting Shp2 mutations cooperate through activation of anti-apoptotic genes. Finally, we show Shp2E76K mutations reduce sensitivity of AML cells to small-molecule-mediated Mcl1 inhibition, suggesting reduced efficacy of drugs targeting MCL1 in patients with hyperactive Shp2.

AB - PTPN11 encodes the Shp2 non-receptor protein-tyrosine phosphatase implicated in several signaling pathways. Activating mutations in Shp2 are commonly associated with juvenile myelomonocytic leukemia but are not as well defined in other neoplasms. Here we report that Shp2 mutations occur in human acute myeloid leukemia (AML) at a rate of 6.6% (6/91) in the ECOG E1900 data set. We examined the role of mutated Shp2 in leukemias harboring MLL translocations, which co-occur in human AML. The hyperactive Shp2E76K mutant, commonly observed in leukemia patients, significantly accelerated MLL-AF9-mediated leukemogenesis in vivo. Shp2E76K increased leukemic stem cell frequency and affords MLL-AF9 leukemic cells IL3 cytokine hypersensitivity. As Shp2 is reported to regulate anti-apoptotic genes, we investigated Bcl2, Bcl-xL and Mcl1 expression in MLL-AF9 leukemic cells with and without Shp2E76K. Although the Bcl2 family of genes was upregulated in Shp2E76K cells, Mcl1 showed the highest upregulation in MLL-AF9 cells in response to Shp2E76K. Indeed, expression of Mcl1 in MLL-AF9 cells phenocopies expression of Shp2E76K, suggesting Shp2 mutations cooperate through activation of anti-apoptotic genes. Finally, we show Shp2E76K mutations reduce sensitivity of AML cells to small-molecule-mediated Mcl1 inhibition, suggesting reduced efficacy of drugs targeting MCL1 in patients with hyperactive Shp2.

UR - http://www.scopus.com/inward/record.url?scp=84930577576&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930577576&partnerID=8YFLogxK

U2 - 10.1038/leu.2015.18

DO - 10.1038/leu.2015.18

M3 - Article

C2 - 25650089

AN - SCOPUS:84930577576

VL - 29

SP - 1290

EP - 1300

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 6

ER -